Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.3 USD | +0.61% | +5.50% | -30.82% |
31/05 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
24/05 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.82% | 498.21Cr | |
+0.82% | 9.32TCr | |
0.00% | 3.96TCr | |
-11.82% | 3.38TCr | |
+64.77% | 2.68TCr | |
-16.10% | 1.54TCr | |
-6.27% | 1.31TCr | |
-11.38% | 1.16TCr | |
-49.19% | 1.03TCr | |
+5.24% | 942.61Cr |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Names Adam Townsend as Chief Operating Officer